Oxford, UK, 17^th December, 2015.

PharmaVentures is pleased to announce that it acted as advisor to Stericool on its sale to Sweden’s Getinge Group, a global leader in infection control and contamination prevention solutions.

Stericool specialises in hydrogen peroxide based solution low temperature sterilizers for emerging markets.  Founded in 2008, Stericool has its headquarters and manufacturing site in Ankara, Turkey. The acquisition will be included under Getinge’s new business category unit Surgical Workflows and will increase potential for growth in East/ South Europe and the rest of the world.

Fintan Walton, Chief Executive of PharmaVentures said: “This is another important cross-border result for one of our clients. PharmaVentures continues to provide valuable advisory services across healthcare M&A and Licensing”.

Ping Shek, Vice President of PharmaVentures said: “Medical device and healthcare equipment groups remain active in M&A as adding complementary businesses to their global platforms augments organic growth”.

For over 23 years, PharmaVentures has acted as advisor to over 700 pharmaceutical and biotechnology clients in transactions; covering licensing, mergers, acquisitions, divestments and joint venture activities for companies.

Oxford, UK, 16^th September 2015:

PharmaVentures is pleased to announce that it provided transaction support to NovioGendix in its sale to MDxHealth SA (Euronext: MDXH.BR). NovioGendix, a privately-held molecular diagnostics company focused on the development of a non-invasive liquid biopsy test for prostate cancer.  It’s proprietary urine-based, molecular biomarker test for prostate cancer offers a low cost “liquid biopsy” method to identify patients at low risk for prostate cancer. This mRNA biomarker test can also help identify men at increased risk of high-grade disease who may benefit most from a prostate biopsy procedure.

Nigel Borshell, Vice President, PharmaVentures, Ltd said: “We are delighted to support NovioGendix and its shareholders in achieving an exit.”

Fintan Walton, Chief Executive, PharmaVentures, Ltd said: “This is another important result for one of our clients. PharmaVentures has established itself as a leading an advisor in M&A and Licensing”.

For the past 23 years, PharmaVentures has acted as advisor to over 700 global pharmaceutical and biotechnology clients in transactions; covering licensing, mergers, acquisitions, divestments and joint venture activities for companies.

OXFORD, UK, June 30th, 2015

PharmaVentures is pleased to announce that it has acted as advisor to CM Technology Oy (CMT) on its divestment of certain assets to Yokogawa Electric Corporation (Yokogawa). The assets relate to CMT’s world leading capabilities in cellular imaging and analysis.

This transaction is the latest in a series of successful global deals in the life science research tools sector for PharmaVentures’ clients.

Fintan Walton, CEO, PharmaVentures, commented: “PharmaVentures is delighted to have delivered a successful and valuable outcome for our client in a sector where deal activity is bouyant.”

Adrian Dawkes, VP, PharmaVentures, who was lead advisor added: “Cellular imaging and analysis technologies are increasingly important in areas such as regenerative medicine and stem cell technology. Japan is leading the way in many aspects of this research and Yokogawa is therefore an ideal home for CMT’s technologies”.

Over the past 23 years, PharmaVentures has acted as advisor to over 700 global pharmaceutical and biotechnology clients in transactions covering licensing, merger, acquisition, divestment and joint venture activities for companies world-wide.

– ends –

OXFORD, UK, May 29th, 2015.

PharmaVentures is pleased to announce that it has acted as advisor to one of the top US pharmaceutical companies in its divestment of one of its manufacturing facilities to a US contract manufacturer. The divestment, completed in mid-May, has led to the protection of hundreds of jobs.

This divestment follows PharmaVentures continued success in M&A including the executing of multiple divestments for several of the largest pharmaceutical companies in the world.

Fintan Walton, CEO, PharmaVentures, commented: “Once again we are delighted to have delivered a successful and valuable outcome for our client and in the process secured hundreds of jobs.”

Nigel Borshell, VP, PharmaVentures, who was lead advisor added: “Our network of interested players in contract manufacturing and R&D plus our rigorous sale process has yet again delivered a positive outcome for our client”.

Over the past 23 years, PharmaVentures has acted as advisor to over 700 global pharmaceutical and biotechnology clients in transactions covering licensing, merger, acquisition, divestment and joint venture activities for companies.

– ends –

About PharmaVentures, Ltd

PharmaVentures is a premier transaction advisory firm; a world leader in partnering, M&A deals and strategic alliances. For the past 23 years, PharmaVentures has acted as advisor on over 700 deal related projects covering licensing, mergers, acquisitions, divestments and joint venture activities for companies world-wide.

Their unrivalled bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes them uniquely placed to support your business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

Find out more www.pharmaventures.com

Their services include:

• M&A (divestments, mergers, acquisitions and strategic transactions)
• Strategy (commercialisation, deal strategy, due diligence, market entry)
• Valuation and Positioning (licensing, M&A, fund raising & expert testimonies)
• Licensing (in and out licensing)
• Expert Testimony (patent infringement, deal disagreements, taxation, determining damages)

Now entering its 24th year, PharmaVentures is based in Oxford, UK, and employs 20 professionals and has associates in North America, Europe, Latin America and Asia-Pacific.

FOR FURTHER INFORMATION, CONTACT:

Dr Fintan Walton

Chief Executive

PharmaVentures Ltd

+44 1865 332700

enquiries@pharmaventures.com